We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
102 own
36 watching
Current Price
$1.17
$-0.13
(-10%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
150.15M
52-Week High
7.61
52-Week Low
1.11
Average Volume
3.35M
Dividend Yield
--
P/E Ratio
--
Market Capitalization150.15M
52-Week High7.61
52-Week Low1.11
Average Volume3.35M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Aviragen Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of direct-acting antivirals to treat infections worldwide. Its product candidates include vapendavir, which is in Phase IIb SPIRITUS trial for an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA585, an oral fusion protein inhibitor, which is in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, an antiviral treatment that is in Phase II development for condyloma caused by human papillomavirus types 6 and 11. Aviragen Therapeutics, Inc. has collaboration agreement with Daiichi-Sankyo for the development of Laninamivir octanoate, a neuraminidase inhibitor, which has completed Phase II clinical trial for the treatment of influenza. The company was formerly known as Biota Pharmaceuticals, Inc. and changed its name to Aviragen Therapeutics, Inc. in April 2016. Aviragen Therapeutics, Inc. is based in Alpharetta, Georgia.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
5days ago
Funding and support provided by Bill & Melinda Gates Foundation Study will focus on determining the ability of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to young infants SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ...
Globe Newswire
14days ago
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine & Immunotherapy Congress West Coast 2022 in San Diego on Tuesday, November 29, 2022 at 1:50 p.m. PT...
PR Newswire
1month ago
Scott+Scott Attorneys at Law LLP and Hagens Berman Sobol Shapiro LLP Announce Pendency of Class Action To All Persons and Entities Who Purchased or Otherwise Acquired Shares of the Common Stock of Vaxart, Inc. During the Period Between June 15, 2020 and August 19, 2020, Inclusive Scott+Scott...
Globe Newswire
1month ago
SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will make separate presentations at the World Vaccine Congress Europe 2022 in ...
Globe Newswire
3 months ago
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will be presenting virtually ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$1.17
$-0.13
(-10%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00